Pharmafile Logo

Dren Bio

- PMLiVE

Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

The deal focuses on T cell-based therapies for autoimmune disease

- PMLiVE

Sanofi reports improved patient outcomes from high-dose influenza vaccine

Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

- PMLiVE

Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

Sha joined Sanofi in 2019 and takes up her new role with immediate effect

- PMLiVE

Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

More than 180,000 people worldwide are diagnosed with the disease every year

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

- PMLiVE

Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

The drug is already approved in the EU across three other multiple myeloma indications

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

The deal includes an early-stage combination vaccine candidate for RSV and hMPV

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

- PMLiVE

Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links